Get the Stockscreener App
23.45
1.16%
0.27
After Hours:
23.45
Overview
News
Price History
Option Chain
Financials
Why PFE Down?
Discussions
Forecast
Stock Split
Dividend History
Pfizer Inc stock is traded at $23.45, with a volume of 26.07M.
It is up +1.16% in the last 24 hours and down -1.43% over the past month.
Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding covid-19-related product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.
See More
Previous Close:
$23.18
Open:
$23.325
24h Volume:
26.07M
Relative Volume:
0.53
Market Cap:
$133.32B
Revenue:
$62.46B
Net Income/Loss:
$7.88B
P/E Ratio:
16.99
EPS:
1.38
Net Cash Flow:
$11.22B
1W Performance:
+1.78%
1M Performance:
-1.43%
6M Performance:
-10.53%
1Y Performance:
-15.71%
1-Day Range:
$23.16
$23.45
1-Week Range:
$22.88
$23.66
52-Week Range:
$20.91
$31.54
Pfizer Inc Stock (PFE) Company Profile
Name
Pfizer Inc
Sector
Industry
Phone
(212) 733-2323
Address
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Compare PFE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
23.45 | 130.99B | 62.46B | 7.88B | 11.22B | 1.38 |
|
LLY
Lilly Eli Co
|
722.57 | 650.81B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
153.58 | 368.56B | 89.33B | 21.81B | 18.57B | 8.99 |
|
ABBV
Abbvie Inc
|
185.62 | 321.13B | 57.37B | 4.20B | 15.39B | 2.35 |
|
NVS
Novartis Ag Adr
|
112.58 | 222.75B | 53.22B | 12.86B | 14.85B | 6.39 |
|
NVO
Novo Nordisk Adr
|
69.46 | 303.04B | 43.59B | 15.04B | 10.74B | 3.3766 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-22-25 | Initiated | Cantor Fitzgerald | Neutral |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-25-24 | Resumed | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Aug-07-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Mar-22-24 | Downgrade | Argus | Buy → Hold |
| Feb-23-24 | Initiated | Guggenheim | Buy |
| Jan-04-24 | Downgrade | TD Cowen | Outperform → Market Perform |
| Oct-20-23 | Resumed | UBS | Neutral |
| Oct-16-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-17-23 | Reiterated | JP Morgan | Neutral |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jun-29-23 | Downgrade | Credit Suisse | Outperform → Neutral |
| May-11-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-07-23 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Jan-26-23 | Downgrade | UBS | Buy → Neutral |
| Jan-17-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-04-23 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-13-22 | Upgrade | Goldman | Neutral → Buy |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Apr-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-05-22 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-20-21 | Reiterated | Cowen | Outperform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-13-21 | Upgrade | UBS | Neutral → Buy |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Jul-27-21 | Resumed | Truist | Buy |
| May-06-21 | Downgrade | Mizuho | Buy → Neutral |
| Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
| Feb-04-21 | Upgrade | DZ Bank | Hold → Buy |
| Dec-16-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-19-20 | Resumed | Goldman | Neutral |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Oct-12-20 | Downgrade | Atlantic Equities | Overweight → Neutral |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-16-20 | Initiated | SVB Leerink | Mkt Perform |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-27-20 | Upgrade | Standpoint Research | Hold → Buy |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Outperform |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Jul-30-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jul-30-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-04-19 | Resumed | Morgan Stanley | Overweight |
| Feb-20-19 | Resumed | Citigroup | Neutral |
| Jan-31-19 | Upgrade | Argus | Hold → Buy |
| Jan-31-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jan-23-19 | Downgrade | UBS | Buy → Neutral |
| Dec-11-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-01-18 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
View All
Pfizer Inc Stock (PFE) Latest News
Pfizer (NYSE:PFE) Ends Collaboration With Acepodia And Faces Depo-Provera Legal Challenges - simplywall.st
Pfizer (PFE) Down 5% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Penicillin Market Research Report 2025 - GlobeNewswire Inc.
Are Investors Undervaluing Pfizer (PFE) Right Now? - Nasdaq
Pfizer's Mega Deal Highlights China's Rising Role In Global Pharma - Benzinga
Berenberg Bank Cuts Pfizer Price Target to $25 From $28, Maintains Hold Rating - marketscreener.com
5 Rock-Solid Dividend Stocks Under $50 With Room to Run - 24/7 Wall St.
Old COVID tweet lands Pfizer in new trouble with PMCPA - pharmaphorum
PFIZER INC : Berenberg reaffirms its Neutral rating - marketscreener.com
Acute Myeloid Leukemia Market Detailed Analysis and Forecast - openPR.com
Pfizer (PFE) Stock Slides Over 2%, Hits Day’s Low in Afternoon Trading - Daily Chhattisgarh News
With 67% ownership of the shares, Pfizer Inc. (NYSE:PFE) is heavily dominated by institutional owners - Yahoo Finance
U.S. Vaccine Market Set to Witness Robust ExpansionPfizer, Moderna - openPR.com
Acepodia and Pfizer To Terminate Cooperation in Autoimmune Diseases Drugs Development - marketscreener.com
Novo Nordisk's 52% Plunge: Is the Company Fumbling Its Leadership in the $150 Billion Weight Loss Market? - The Motley Fool
FDA Warns of Heart Risk With Pfizer, Moderna COVID Vaccines - Endocrinology Advisor
Unlocking Pfizer's Value: Cost Controls And Oncology Pipeline - Seeking Alpha
US drops COVID vaccine recommendation for healthy kids, pregnant women - marketscreener.com
Mixed options sentiment in Pfizer with shares up 0.88% - TipRanks
US drops COVID vaccine recommendations for healthy children, pregnant women - marketscreener.com
Sleep Aids Market Generated Opportunities, Future Scope - openPR.com
Is Pfizer Stock a Buy After This $1.25 Billion Investment? - The Globe and Mail
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Enamine to Enable Access to Selected Pfizer Reference Compounds to Support the Global Research CommunityMETRO - METRO - NEWS CHANNEL NEBRASKA
Specialty Injectable Generics Market Is Booming So Rapidly - openPR.com
Immunostimulant Drugs Market Is Booming So Rapidly 2025-2032 - openPR.com
Chlorphenamine Maleate API Market Trends, Demand, and Future Outlook | Pfizer Inc., Novartis AG, Sanofi S.A. - openPR.com
Pfizer, Inc. (PFE) Stock Analysis: Evaluating a 26.50% Potential Upside Amidst Challenges - DirectorsTalk Interviews
Investing In The Promising PD1/VEGF Bispecific; Pfizer And Instil Could Be Good Candidates - Seeking Alpha
Pfizer (PFE) Secures $1.25B Cancer Drug Licensing Deal - GuruFocus
25,379 Shares in Pfizer Inc. (NYSE:PFE) Bought by PVG Asset Management Corp - InsuranceNewsNet
Pfizer’s SWOT analysis: stock outlook amid strategic moves and pipeline potential - Investing.com India
Pfizer Inc. (PFE) Delivers Oncology Milestones with MesoC2 Debut and XTANDI Survival Boost - Yahoo Finance
Down 63%, Should You Buy the Dip on Pfizer? - AOL.com
Pfizer's 7.5% Dividend: Income Haven or House of Cards? - MSN
Pfizer (NYSE:PFE) Showcases New Cancer Treatment Study And Reports Prostate Cancer Drug Success - simplywall.st
Type 2 Diabetes Market to Expand Significantly by 2034, States DelveInsight Report | Eli Lilly and Company, Regor Pharma, AstraZeneca, Eccogene, Pfizer, Sciwind Biosciences USA Co., Ltd., MediciNova - The Globe and Mail
Pfizer Inks $1.25 Billion Deal with 3SBio for Global Rights to Cancer Drug - Contract Pharma
FDA Advisory Panel Backs COVID Vaccine Update, Impacting Pfizer (PFE) - GuruFocus
Nona Biosciences Collaboration Partner Pfizer Announces Presentation of Phase 1 Clinical Study Design on MesoC2, an MSLN-Targeting ADC, at the 2025 ASCO Annual Meeting - PR Newswire
Astellas and Pfizer's XTANDI Shows Long-Term Overall Survival in Metastatic Hormone-Sensitive Prostate Cancer - Investing News Network
Fed. Circ. Backs Pfizer Win Against Gene Therapy Patents - Law360
Astellas and Pfizer’s XTANDI™ (enzalutamide) Shows Long-Term Overall Survival in Metastatic Hormone-Sensitive Prostate Cancer - Pfizer
Pfizer, Astellas Pharma's Prostate Cancer Treatment Shows 30% Reduction in Risk of Death - marketscreener.com
Astellas and Pfizer's XTANDI™ (enzalutamide) Shows Long-Term Ove - GuruFocus
Was Jim Cramer Right About Pfizer Inc. (PFE)? - Yahoo Finance
Astellas and Pfizer's XTANDI™ (enzalutamide) Shows Long-Term Overall Survival in Metastatic Hormone-Sensitive Prostate Cancer - Yahoo Finance
COVID shots should target newer strains of JN.1 variant, US FDA advisers say - marketscreener.com
Pfizer Cements Win Axing Hemophilia Patents at Federal Circuit - Bloomberg Law News
Was Jim Cramer Right About These 12 Stocks? - Insider Monkey
Changes are happening around COVID-19 vaccines: Here's what to know - USA Today
Pfizer Inc Stock (PFE) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.46%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):